Business Context and Reporting Period
Company: Ascentage Pharma Group International
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2026
Date of Filing: July 13, 2026
Principal Executive Offices: Suzhou, Jiangsu, China
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding equity compensation and does not contain financial statements.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely discloses an update on equity award grants.
Management Commentary and Unusual Items
Equity Compensation Update: On July 13, 2026, the company issued an announcement regarding the further grant of awards under the following schemes:
- 2021 Restricted Stock Unit (RSU) Scheme
- 2022 Restricted Stock Unit (RSU) Scheme
- Post IPO Share Option Scheme
Investor Verification Checklist
- Review the full text of the announcement furnished as Exhibit 99.1 for specific details on the number of awards granted and recipients.
- Verify the impact of these new grants on the company's total outstanding share count and potential dilution.
- Confirm the vesting schedules and exercise terms associated with the 2021 RSU, 2022 RSU, and Post IPO Share Option schemes.